BR100 Increased By (0.27%)
BR30 Increased By (0.15%)
KSE100 Increased By (0.15%)
KSE30 Increased By (0.01%)
BECO 5.92 Decreased By ▼ -0.11 (-1.82%)
BML 57.31 Increased By ▲ 4.56 (8.64%)
BOP 34.09 Decreased By ▼ -0.16 (-0.47%)
CNERGY 8.20 Increased By ▲ 0.04 (0.49%)
DCL 12.15 Decreased By ▼ -0.19 (-1.54%)
FCCL 53.88 Decreased By ▼ -0.01 (-0.02%)
FCSC 5.25 Increased By ▲ 0.03 (0.57%)
FFL 18.01 Decreased By ▼ -0.02 (-0.11%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.23 Increased By ▲ 0.23 (2.09%)
KEL 8.17 Increased By ▲ 0.06 (0.74%)
KOSM 5.47 Increased By ▲ 0.09 (1.67%)
MLCF 88.79 Increased By ▲ 0.74 (0.84%)
NBP 186.50 Increased By ▲ 0.02 (0.01%)
PACE 10.96 Increased By ▲ 0.24 (2.24%)
PAEL 40.42 Increased By ▲ 0.48 (1.2%)
PIAHCLA 26.26 Increased By ▲ 0.09 (0.34%)
PIBTL 17.33 Increased By ▲ 0.01 (0.06%)
PPL 232.00 Decreased By ▼ -0.78 (-0.34%)
PRL 34.70 Decreased By ▼ -0.25 (-0.72%)
PTC 66.80 Decreased By ▼ -0.76 (-1.12%)
SEARL 91.45 Increased By ▲ 0.52 (0.57%)
SSGC 27.15 Decreased By ▼ -0.02 (-0.07%)
TELE 8.70 Increased By ▲ 0.13 (1.52%)
THCCL 65.35 Increased By ▲ 5.22 (8.68%)
TPLP 9.20 Increased By ▲ 0.44 (5.02%)
TREET 24.55 Increased By ▲ 0.01 (0.04%)
TRG 72.63 Increased By ▲ 0.88 (1.23%)
WAVES 10.70 Increased By ▲ 0.72 (7.21%)
WTL 1.26 No Change ▼ 0.00 (0%)
By

NEW YORK: The US Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer and BioNTech Covid-19 vaccine for children aged between 12 and 15 years, and narrowed the time for all booster shots to 5 months from 6 months after primary doses.

The agency also authorized a third shot in children aged 5 through 11 years who are immunocompromised. The FDA said it reviewed published data and real world evidence on the safety of booster doses provided by the Israeli Ministry of Health including data from over 6,300 individuals 12-to-15 years of age who received a Pfizer shot.

Global COVID-19 cases are surging due to the Omicron variant and health authorities have warned that its extremely high transmissibility could overwhelm many health systems. Laboratory tests have shown that two doses of the Pfizer-BioNTech and Moderna vaccines generate low immune responses against Omicron, while boosters appear to be protective against the highly-mutated variant.

Comments

Comments are closed for this article.